Problem → Hypothesis → Methodology → Results
Autoimmune diseases affect millions globally. Current treatments cause severe systemic side effects due to lack of specificity, compromising healthy immune function and quality of life.
ADCs targeting RORγt will selectively bind disease-causing Th17 cells, delivering therapeutic payload with high specificity and minimal off-target toxicity.
Computational drug design using AutoDock Vina for molecular docking, PyMOL for visualization, binding affinity calculations, and 3D structure modeling.
Achieved 100% in silico validation, confirming stable ADC-RORγt complex formation and therapeutic potential.